Mechanistic and functional differentiation of tapentadol and tramadol

Bibliography

• Nicholls A, McGaughey GB, Sheridan RP, Molecular shape and medicinal chemistry: a perspective. J Med Chem 2010;53:3862-86
   PubMed Web of Science ®Google Scholar
• Levi P. Other people's trades. Summit Books; New York, NY: 1989
   Google Scholar
• Bemis GW, Murcko MA. The properties of known drugs. 1. Molecular frameworks. J Med Chem 1996;39:2887-93
   PubMed Web of Science ®Google Scholar
• Hu Y, Bajorath J. Polypharmacology directed compound data mining: identification of promiscuous chemotypes with different activity profiles and comparison to approved drugs. J Chem Inf Model 2010;50:2112-18
   PubMed Web of Science ®Google Scholar
• Anderson E, Veith GD, Weininger D. SMILES: a line notation and computerized interpreter for chemical structures. Report No. EPA/600/M-87/021; U.S EPA, Environmental Research Laboratory—Duluth; Duluth, MN: 1987
   Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26
   PubMed Web of Science ®Google Scholar
• Hahn M. Three-dimensional shape-based searching of conformationally flexible compounds. J Chem Inf Comput Sci 1997;37:80-6
   Google Scholar
• Raffa RB, Tallarida RJ. Affinity: historical development in chemistry and pharmacology. Bull Hist Chem 2010;35:7-16
   Google Scholar
• Tao Q, Stone DJ, Borenstein MR, Differential tramadol and O-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally. J Clin Pharm Ther 2002;27:99-106
   PubMed Web of Science ®Google Scholar
• Casy AF, Parfitt RT. Opioid analgesics - chemistry and receptors. Plenum Press; New York, NY: 1986
   Google Scholar
• Maul C, Buschmann H, Sundermann B. Synthetic opioids. In: Buschmann H, Christoph T, Friderichs E, editors. Analgesics. Wiley-VCH; Weinheim, Germany: 2002. p. 159-69
   Google Scholar
• Friderichs E, Buschmann H. Opioids with clinical relevance. In: Buschmann H, Christoph T, Friderichs E, editors. Analgesics – from chemistry and pharmacology to clinical application. Wiley-VCH; Weinheim, Germany: 2002. p. 171-245
   Google Scholar
• Hu Y, Stumpfe D, Bajorath J. Lessons learned from molecular scaffold analysis. J Chem Inf Model 2011;51:1742-53
   PubMed Web of Science ®Google Scholar
• Ferenczy GG, Keseru GM. Thermodynamics guided lead discovery and optimization. Drug Discov Today 2010;15:919-32
   PubMed Web of Science ®Google Scholar
• Reynolds CH, Holloway CK. Thermodynamics of ligand binding and efficiency. ACS Med Chem Lett 2011;2:433-7
   PubMed Web of Science ®Google Scholar
• Gleeson MP, Hersey A, Montanari D, Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov 2011;10:197-208
   PubMed Web of Science ®Google Scholar
• Bohm H-J, Gerard Klebe G, Kubinyi H. Wirkstoffdesign - Der Weg zum Arzneimittel. Spektrum Akademischer Verlag; Heidelberg, Germany: 1996
   Google Scholar
• Agranat I, Caner H, Caldwell J. Putting chirality to work: the strategy of chiral switches. Nat Rev Drug Discov 2002;1:753-68
   PubMed Web of Science ®Google Scholar
• Federsel H-J. Putting chirality to work: the strategy of chiral switches. Chirality 2003;15:128-42
   PubMed Web of Science ®Google Scholar
• Wermuth CG. The Practice of Medicinal Chemistry. Academic Press; Burlington, MA: 2008
   Google Scholar
• Milletti F, Vulpetti A. Predicting polypharmacology by binding site similarity: from kinases to the protein universe. J Chem Inf Model 2010;50:1418-31
   PubMed Web of Science ®Google Scholar
• Bottegoni G, Favia AD, Recanatini M, Cavalli A. The role of fragment-based and computational methods in polypharmacology. Drug Discov Today 2012;17:23-34
   PubMed Web of Science ®Google Scholar
• Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet 2011;377:2226-35
   PubMed Web of Science ®Google Scholar
• Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005;48:6523-43
   PubMed Web of Science ®Google Scholar
• Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12:34-42
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kögel B, (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel µ−opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-76
   PubMed Web of Science ®Google Scholar
• Lai J, Ma SW, Porreca F, Raffa RB. Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur J Pharmacol 1996;316:369-72
   PubMed Web of Science ®Google Scholar
• Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 2000;362:116-21
   PubMed Web of Science ®Google Scholar
• Bloms-Funke P, Dremencov E, Cremers TI, Tzschentke TM. Tramadol increases extracellular levels of serotonin and noradrenaline as measured by in vivo microdialysis in the ventral hippocampus of freely-moving rats. Neurosci Lett 2011;490:191-5
   PubMed Web of Science ®Google Scholar
• Ceccato A, Vanderbist F, Pabst JY, Streel B. Enantiomeric determination of tramadol and its main metabolite O-desmethyltramadol in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2000;748:65-76
   PubMed Web of Science ®Google Scholar
• Schroder W, Vry JD, Tzschentke TM, Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010;14:814-21
   PubMed Web of Science ®Google Scholar
• Schiene K, De VJ, Tzschentke TM. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain. J Pharmacol Exp Ther 2011;339:537-44
   PubMed Web of Science ®Google Scholar
• Raffa RB, Friderichs E, Reimann W, Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther 1992;260:275-85
   PubMed Web of Science ®Google Scholar
• Schroder W, Tzschentke TM, Terlinden R, Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011;337:312-20
   PubMed Web of Science ®Google Scholar
• Raffa RB, Nayak RK, Liao S, Minn FL. The mechanism(s) of action and pharmacokinetics of tramadol hydrochloride. Rev Contemp Pharmacother 1995;6:485-97
   Google Scholar
• Garcia-Quetglas E, Azanza JR, Sadaba B, Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res 2007;55:122-30
   PubMed Web of Science ®Google Scholar
• Klotz U. Tramadol–the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung 2003;53:681-7
   PubMed Web of Science ®Google Scholar
• Terlinden R, Kögel BY, Englberger W, Tzschentke TM. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 2010;32:31-8
   PubMedGoogle Scholar
• Kneip C, Terlinden R, Beier H, Chen G. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett 2008;2:67-75
   PubMedGoogle Scholar
• Nagar S, Raffa RB. Looking beyond the administered drug: metabolites of opioid analgesics. J Fam Pract 2008;57:S1-8
   PubMedGoogle Scholar
• Holmquist GL. Opioid metabolism and effects of cytrochrome P450. Pain Med 2009;10:S20-9
   Web of Science ®Google Scholar
• Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 2009;65:121-39
   PubMed Web of Science ®Google Scholar
• Lange B, Kuperwasser B, Okamoto A, Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99
   PubMed Web of Science ®Google Scholar
• Jarlbaek L, Andersen M, Hallas J, Use of opioids in a Danish population-based cohort of cancer patients. J Pain Symptom Manage 2005;29:336-43
   PubMed Web of Science ®Google Scholar
• Aulbert E, Nauck F, Radbruch L. editors. Lehrbuch der Palliativmedizin. Schattauer Verlag; Stuttgart, Germany: 2006
   Google Scholar
• Vissers KC, Besse K, Hans G, Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract 2010;10:85-93
   PubMed Web of Science ®Google Scholar
• ULTRAM® ER (tramadol HCl) Extended Release Tablets [package insert]. PriCara™ Unit of Ortho-McNeil, Inc., Raritan, NJ:2007
   Google Scholar
• Nucynta® ER (tapentadol) extended-release oral tablets C-II [package insert]. Janssen Pharmaceuticals, Inc.; Raritan, NJ: 2011
   Google Scholar
• Cossmann M, Kohnen C. General tolerability and adverse event profile of tramadol hydrochloride. Rev Contemp Pharmacother 1995;6:513-31
   Google Scholar
• Bamigbade TA, Langford RM. The clinical use of tramadol hydrochloride. Pain Rev 1998;5:155-82
   Web of Science ®Google Scholar
• Barkin RL. Extended-release tramadol (ULTRAM ER): a pharmacotherapeutic, pharmacokinetic, and pharmacodynamic focus on effectiveness and safety in patients with chronic/persistent pain. Am J Ther 2008;15:157-66
   PubMed Web of Science ®Google Scholar
• Riemsma R, Forbes C, Harker J, Systematic review of tapentadol in chronic severe pain. Curr Med Res Opin 2011;27:1907-30
   PubMed Web of Science ®Google Scholar
• Hoy SM. Tapentadol extended release: in adults with chronic pain. Drugs 2012;72:375-93
   PubMed Web of Science ®Google Scholar
• Daniels SE, Golf M. Clinical efficacy and safety of tapentadol immediate release in the postoperative setting. J Am Podiatr Med Assoc 2012;102:139-48
   PubMed Web of Science ®Google Scholar
• Merker M, Dinges G, Koch T, Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies. Schmerz 2012;26:16-26
   PubMed Web of Science ®Google Scholar
• Dayer P, Desmeules J, Collart L. Pharmacology of tramadol. Drugs 1997;53(Suppl 2):18-24
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Inciardi JA, Adams EH, Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf 2005;14:851-9
   PubMed Web of Science ®Google Scholar
• Adams EH, Breiner S, Cicero TJ, A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage 2006;31:465-76
   PubMed Web of Science ®Google Scholar
• Inciardi JA, Cicero TJ, Munoz A, The diversion of Ultram®, Ultracet®, and generic tramadol HCl. J Addict Dis 2006;25:53-8
   PubMed Web of Science ®Google Scholar
• Hartrick C, Van Hove I, Stegmann J-U, Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther 2009;31:260-71
   PubMed Web of Science ®Google Scholar
• Daniels SE, Upmalis D, Okamoto A, A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009;25:765-76
   PubMed Web of Science ®Google Scholar
• Afilalo M, Etropolski MS, Kuperwasser B, Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30:489-505
   PubMed Web of Science ®Google Scholar
• Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 2010;14:781-3
   PubMed Web of Science ®Google Scholar
• Fields HL, Martin JB. Pain: pathophysiology and management. In: Gaul C, Endres M, Erbguth F. editors. Harrison's neurology in clinical medicine; german edition. ABW Wissenschaftsverlag; Berlin, Germany: 2012;12:290-306
   Google Scholar
• Pergolizzi J, Alon E, Baron R, Tapentadol in the management of chronic low back pain: a novel approach to a complex condition? J Pain Res 2011;4:203-10
   PubMedGoogle Scholar
• Pergolizzi J, Alegre C, Blake D, Current considerations for the treatment of severe chronic pain: the potential for tapentadol. Pain Pract 2012
   Web of Science ®Google Scholar
• Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 2004;25:613-17
   PubMed Web of Science ®Google Scholar
• Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics 2009;6:703-12
   PubMed Web of Science ®Google Scholar
• Raffa RB, Friderichs E, Reimann W, Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993;267:331-40
   PubMed Web of Science ®Google Scholar